Satellos Bioscience Inc. (TSX:MSCL)

Canada flag Canada · Delayed Price · Currency is CAD
0.5800
-0.0100 (-1.69%)
Jun 12, 2025, 3:59 PM EDT
-1.69%
Market Cap 102.26M
Revenue (ttm) n/a
Net Income (ttm) -29.55M
Shares Out 176.31M
EPS (ttm) -0.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 219,200
Average Volume 266,781
Open 0.5900
Previous Close 0.5900
Day's Range 0.5800 - 0.5900
52-Week Range 0.4500 - 1.3200
Beta 0.67
RSI 40.91
Earnings Date Aug 12, 2025

About Satellos Bioscience

Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British C... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 17
Stock Exchange Toronto Stock Exchange
Ticker Symbol MSCL
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.